Suche Struktur Suche
wx_img
Inquiry Form
  1. Home
  2. Glecirasib

Glecirasib

On January 20, Jacobio Pharma presents data of glecirasib in patients with pancreatic cancer and other solid tumors at the 2024 ASCO GI. For second-line and above KRAS G12C mutated pancreatic cancer patients, the confirmed objective response rate (cORR) was 41.9% and the disease control rate (DCR) was 93.5%. Glecirasib is a potential best-in-class KRAS G12C allosteric inhibitor with promising early clinical efficacy. Glecirasib can be used as monotherapy to treat non-small cell lung cancer, colorectal cancer and other solid tumors with the KRAS G12C mutation. Combinations of Glecirasib with SHP2i, EGFRi, or PD-1 antibodies is expected to have synergistic efficacy and overcome acquired drug resistance.

4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane
4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane
CM100150
126726-62-3
3-Amino-2-bromo-4-picoline
3-Amino-2-bromo-4-picoline
CM102708
126325-50-6
4-methyl-2-propan-2-ylpyridin-3-amine
4-methyl-2-propan-2-ylpyridin-3-amine
CM325577
1698293-93-4
2,5,6-trichloronicotinic acid
2,5,6-trichloronicotinic acid
CM178138
54718-39-7
2-cyano-N-(2-isopropyl-4-methyl-3-pyridyl)acetamide
2-cyano-N-(2-isopropyl-4-methyl-3-pyridyl)acetamide
CM1018507
2397623-38-8
2,3,4,5-tetrafluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
2,3,4,5-tetrafluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
CM1075242
2657617-90-6
2,3,4,5-Tetrafluoroaniline
2,3,4,5-Tetrafluoroaniline
CM118575
5580-80-3
2-bromo-3,4,5,6-tetrafluoroaniline
2-bromo-3,4,5,6-tetrafluoroaniline
CM776044
5580-82-5